AstraZeneca beats expectations on cancer drug demand
RTE
—
AstraZeneca has today beaten first-quarter sales and profit expectations and maintained its 2026 outlook, as demand for its cancer drugs and investments in key markets helped the drugmaker navigate a complex geopolitical landscape.
AstraZeneca beats expectations
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies CNBC —
- Astrazeneca tops expectations in the first quarter on strong cancer drug sales Associated Press —
- AstraZeneca posted stronger-than-expected profit and revenue on surging cancer drug sales Quartz —
- AstraZeneca makes surprise U-turn with £300m pharma investment The Guardian —
- Shot in the arm for GSK and AstraZeneca from cancer drug sales The Argus —